Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) – Equities researchers at Cantor Fitzgerald issued their FY2019 EPS estimates for Arrowhead Pharmaceuticals in a note issued to investors on Thursday, October 17th. Cantor Fitzgerald analyst A. Young expects that the biotechnology company will post earnings per share of $0.67 for the year. Cantor Fitzgerald has a “Neutral” rating on the stock. Cantor Fitzgerald also issued estimates for Arrowhead Pharmaceuticals’ FY2020 earnings at ($0.05) EPS.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its earnings results on Monday, August 5th. The biotechnology company reported $0.21 EPS for the quarter, missing the consensus estimate of $0.34 by ($0.13). The business had revenue of $42.70 million during the quarter, compared to analysts’ expectations of $59.05 million. Arrowhead Pharmaceuticals had a net margin of 33.28% and a return on equity of 26.27%.
Several other research firms have also commented on ARWR. Robert W. Baird began coverage on Arrowhead Pharmaceuticals in a report on Wednesday, October 2nd. They issued an “outperform” rating and a $39.00 target price on the stock. B. Riley increased their target price on Arrowhead Pharmaceuticals from $32.00 to $46.00 and gave the company a “buy” rating in a report on Monday, August 19th. Piper Jaffray Companies increased their target price on Arrowhead Pharmaceuticals from $50.00 to $54.00 and gave the company an “overweight” rating in a report on Sunday. ValuEngine lowered Arrowhead Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Finally, BidaskClub raised Arrowhead Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Wednesday, October 9th. Two equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $41.60.
NASDAQ:ARWR opened at $38.97 on Monday. The firm has a market capitalization of $3.41 billion, a PE ratio of -59.95 and a beta of 1.48. The business’s fifty day moving average price is $31.11 and its 200 day moving average price is $26.70. Arrowhead Pharmaceuticals has a 12 month low of $10.41 and a 12 month high of $39.25.
Several hedge funds have recently modified their holdings of the business. Nisa Investment Advisors LLC grew its holdings in shares of Arrowhead Pharmaceuticals by 96.2% during the third quarter. Nisa Investment Advisors LLC now owns 1,020 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 500 shares during the last quarter. United Services Automobile Association grew its holdings in shares of Arrowhead Pharmaceuticals by 2.6% during the second quarter. United Services Automobile Association now owns 20,515 shares of the biotechnology company’s stock worth $544,000 after purchasing an additional 522 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Arrowhead Pharmaceuticals by 10.3% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,701 shares of the biotechnology company’s stock worth $161,000 after buying an additional 531 shares during the period. Royal Bank of Canada boosted its stake in shares of Arrowhead Pharmaceuticals by 1.2% during the second quarter. Royal Bank of Canada now owns 71,303 shares of the biotechnology company’s stock worth $1,889,000 after buying an additional 842 shares during the period. Finally, Envestnet Asset Management Inc. boosted its stake in shares of Arrowhead Pharmaceuticals by 3.2% during the second quarter. Envestnet Asset Management Inc. now owns 32,047 shares of the biotechnology company’s stock worth $849,000 after buying an additional 996 shares during the period. 72.00% of the stock is currently owned by institutional investors.
In other Arrowhead Pharmaceuticals news, CEO Christopher Richard Anzalone sold 66,645 shares of the firm’s stock in a transaction dated Tuesday, September 24th. The stock was sold at an average price of $28.20, for a total transaction of $1,879,389.00. Following the transaction, the chief executive officer now owns 2,146,153 shares of the company’s stock, valued at $60,521,514.60. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Michael S. Perry sold 85,000 shares of the firm’s stock in a transaction dated Wednesday, September 11th. The stock was sold at an average price of $30.00, for a total value of $2,550,000.00. Following the transaction, the director now directly owns 121,000 shares in the company, valued at approximately $3,630,000. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 312,220 shares of company stock worth $9,235,464. Corporate insiders own 4.80% of the company’s stock.
Arrowhead Pharmaceuticals Company Profile
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's pipeline include ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma.
Featured Story: Stock Symbols, CUSIP and Other Stock Identifiers
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.